Daikoku Tohru, Tannai Hidenori, Honda Mariko, Onoe Tomohiko, Matsuo Koma, Onoye Yasuhiko, Nishizawa Mika, Kawana Takashi, Okuda Tomoko, Hasegawa Tomomi, Shiraki Kimiyasu
Department of Virology, University of Toyama, Toyama 930-0194, Japan.
Department of Dermatology, The Jikei University School of Medicine, Tokyo 105-8471, Japan.
J Dermatol Sci. 2016 Jun;82(3):160-5. doi: 10.1016/j.jdermsci.2016.02.006. Epub 2016 Feb 15.
Suppressive therapy in patients with genital herpes has been used in Japan since 2006. Susceptibility and resistance of herpes simplex virus (HSV)-2 to acyclovir were examined in genital isolates from patients receiving suppressive therapy and compared with those from those naïve to acyclovir and receiving episodic treatment with acyclovir.
The aim of this study was to analyze the effect of acyclovir use on the susceptibility to acyclovir and analysis of the thymidine kinase gene by acyclovir treatment.
Genital HSV isolates were obtained from three patients groups. Susceptibility to acyclovir, the frequency of acyclovir-resistant clones and mutations in the thymidine kinase gene of acyclovir-resistant clones were determined.
Susceptibility to ACV was significantly higher in isolates from patients receiving suppressive therapy than those naïve to acyclovir and receiving episodic treatment, but the frequencies of resistant clones were similar among the three groups. Mutation in guanosine homopolymeric strings (G-string mutation) was significantly more frequent in clones during episodic treatment and suppressive therapy than clones from patients naïve to ACV. The frequency of G-string mutation was significantly less frequent in isolates from patients naïve to ACV than those experienced ACV therapy.
The frequency of acyclovir-resistant mutants was not increased by episodic and suppressive therapy, but exposure to acyclovir significantly generated G-string mutations, possibly induced by acyclovir. Acyclovir therapy had no substantial effects on the susceptibility of HSV-2 or frequency of resistant virus but did generate subclinical G-string mutants in patients' HSV-2.
自2006年起,日本开始对生殖器疱疹患者采用抑制性疗法。对接受抑制性疗法患者的生殖器分离株中单纯疱疹病毒2型(HSV-2)对阿昔洛韦的敏感性和耐药性进行检测,并与未接触过阿昔洛韦且接受阿昔洛韦发作期治疗的患者的分离株进行比较。
本研究旨在分析阿昔洛韦的使用对阿昔洛韦敏感性的影响以及通过阿昔洛韦治疗对胸苷激酶基因进行分析。
从三组患者中获取生殖器HSV分离株。测定对阿昔洛韦的敏感性、阿昔洛韦耐药克隆的频率以及阿昔洛韦耐药克隆胸苷激酶基因中的突变情况。
接受抑制性疗法患者的分离株对阿昔洛韦的敏感性显著高于未接触过阿昔洛韦且接受发作期治疗的患者,但三组中耐药克隆的频率相似。在发作期治疗和抑制性疗法期间的克隆中,鸟苷同聚物串突变(G串突变)显著多于未接触过阿昔洛韦患者的克隆。未接触过阿昔洛韦患者的分离株中G串突变的频率显著低于接受过阿昔洛韦治疗的患者。
发作期和抑制性疗法并未增加阿昔洛韦耐药突变体的频率,但接触阿昔洛韦会显著产生G串突变,可能是由阿昔洛韦诱导的。阿昔洛韦疗法对HSV-2的敏感性或耐药病毒的频率没有实质性影响,但确实在患者的HSV-2中产生了亚临床G串突变体。